Abstract

The peak of second wave of corona virus disease in India was from mid March to mid May 2021 which was lethal. The present study was carried out with the objectives to find the characteristics, clinical presentation of patients and to co-relate these features with treatment outcomes - mortality and adverse effects. This is an observational study carried out in patients admitted in a Dedicated COVID Hospital (DCH) with severe symptoms of COVID-19 with or without undergoing lab test for diagnosis. The patients were prospectively evaluated for demographics, clinical course, treatment offered and outcomes during a period from 15 April to 19 May 2021. Patients in age group of 45-61 years were most affected. Men were affected more as compared to women. All patients were offered treatment protocol as per updated National guidelines. Primary outcomes in terms of In- hospital mortality was 24.13% The In- hospital mortality was significantly more in patents above the age of 45 years as compared to patients below 45 years and also in patients with co-morbidity than in patients without it. The biomarkers of patients who died were found to be on higher side. Secondary outcomes –death post discharge was 8.04% and 2.29% of patients developed mucormycosis. All the admitted patients had severe symptoms irrespective of confirmatory diagnosis and High –resolution computed tomography (HRCT) scores. All of them required mechanical ventilation, injection Remdisivir, injectable antibiotics, anti-coagulants, injection Methyl Prednisolone. Inspite of this management the In-hospital mortality was 24.13%.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call